This Article Abstract Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Funakoshi, Y. Articles by Takeshita, A. Search for Related Content PubMed PubMed Citation Articles by Funakoshi, Y. Articles by Takeshita, A. Related Collections Gene expression Growth factors/cytokines Mechanism of atherosclerosis/growth factors

(Hypertension. 2001;38:100.)
© 2001 American Heart Association, Inc.

Scientific Contributions

Rho-Kinase Mediates Angiotensin II-Induced Monocyte Chemoattractant Protein-1 Expression in Rat Vascular Smooth Muscle Cells

Yuko Funakoshi; Toshihiro Ichiki; Hiroaki Shimokawa; Kensuke Egashira; Kotaro Takeda; Kozo Kaibuchi; Motohiro Takeya; Teizo Yoshimura; Akira Takeshita

From the Department of Cardiovascular Medicine, Kyushu University Graduate School of Medical Sciences (Y.F., T.I., H.S., K.E., K.T., K.K., A.T.), Fukuoka, Japan; the Second Department of Pathology, Kumamoto University School of Medicine (M.T.), Kumamoto, Japan; and the Immunopathology Section, Laboratory of Immunobiology, National Cancer Institute, Frederic Cancer Research and Developmental Center (T.Y.), Frederick, Md.

Correspondence to Toshihiro Ichiki, MD, Department of Cardiovascular Medicine, Kyushu University Graduate School of Medical Sciences, 3-1-1 Maidashi, Higashi-ku, 812-8582 Fukuoka, Japan. E-mail ichiki{at}cardiol.med.kyushu-u.ac.jp

	Abstract

Top Abstract Introduction Methods Results Discussion References

 
Abstract—— Recently, it was shown that Rho-kinase plays an important role in blood pressure regulation. However, it is not known whether Rho-kinase is involved in atherogenesis. Monocyte chemoattractant protein-1 (MCP-1) is an important chemokine that regulates monocyte recruitment and atherogenesis. Therefore, we examined the role of Rho and Rho-kinase in the angiotensin (Ang) II-induced expression of MCP-1. Ang II dose- and time-dependently enhanced the expression of MCP-1 mRNA and the protein production in vascular smooth muscle cells. CV11974, an Ang II type 1 receptor (AT₁-R) specific antagonist inhibited the enhancement of MCP-1 expression by Ang II, suggesting that the effect of Ang II is mediated by the AT₁-R. Botulinum C3 exotoxin, a specific inhibitor of Rho, suppressed Ang II-induced MCP-1 production. To examine the role of Rho-kinase in Ang II-induced MCP-1 expression, we used adenovirus-mediated overexpression of the dominant negative mutant of Rho-kinase (AdDNRhoK) or Y-27632, a specific inhibitor of Rho-kinase. Both AdDNRhoK and Y-27632 strongly inhibited Ang II-induced MCP-1 expression. Although inhibition of extracellular signal-regulated protein kinase (ERK) by PD 098,059 also inhibited Ang II-induced MCP-1 expression, Y-27632 did not affect Ang II-induced activation of ERK. These results indicate that Rho-kinase plays a critical role in Ang II-induced MCP-1 production independent of ERK. The Rho-Rho-kinase pathway may be a novel target for the inhibition of Ang II signaling and the treatment of atherosclerosis.

Key Words: angiotensin II • peptides • muscle, smooth, vascular • receptors, angiotensin • kinase

	Introduction

Top Abstract Introduction Methods Results Discussion References

 
Angiotensin (Ang) II has been known to regulate blood pressure, fluid homeostasis, and electrolyte balance.¹ Recent studies have shown that Ang II plays an important role in atherogenesis as well. The physiological functions of Ang II are transmitted into target cells through its specific receptor located in the plasma membrane. Although there are 2 isoforms for the Ang II receptor, the Ang II type 1 receptor (AT₁-R)² and the Ang II type 2 receptor (AT₂-R),³ most of the cardiovascular effects of Ang II are ascribed to AT₁-R. Vascular smooth muscle cells (VSMCs) express AT₁-R, and Ang II induces the production of growth factors and extracellular matrices through this receptor. We have recently reported that Ang II induced interleukin-6 production in VSMCs and have proposed that the Ang II-induced cytokine plays an important role in the progression of atherosclerosis.⁴

Invasion of monocytes into the blood vessel wall is one of the early steps in the development of atherosclerosis. Various cytokines, such as monocyte chemoattractant protein-1 (MCP-1),⁵ macrophage inflammatory protein-1,⁶ and RANTES (regulated on activation, normal T-expressed and -secreted),⁷ are known to regulate the movement of monocytes. Among these factors, MCP-1 is one of the most potent chemoattractants for monocytes or macrophages in vitro and in vivo. MCP-1 expression is induced in response to tumor necrosis factor- or -interferon,⁸ thrombin,⁹ or interleukin-1ß¹⁰ in VSMCs. Pathological conditions such as hypercholesterolemia and vascular injury also induce expression of the MCP-1 gene in the vascular wall. Recent studies have suggested that MCP-1 is critical for the progression of atherosclerosis. Targeted disruption of the receptor for MCP-1 (CCR2) attenuated the development of atherosclerosis when the mice were crossed with apoE knockout mice that develop severe atherosclerosis.¹¹

Rho-kinase, identified as a downstream target of Rho A, has been shown to phosphorylate the myosin-binding subunit of myosin light chain phosphatase and enhance smooth muscle contraction.^12,13 Y-27632, a specific inhibitor of Rho-kinase, is reported to reduce blood pressure in hypertensive rats but not in normotensive rats.¹⁴ Recently, a role of Rho A in Ang II-induced actin organization in cardiac myocytes has been reported.¹⁵ However, the role of Rho and Rho-kinase in Ang II-induced gene expression has not been determined. In the present study, we examined whether Rho and Rho-kinase were involved in Ang II-induced MCP-1 expression in VSMCs.

	Methods

Top Abstract Introduction Methods Results Discussion References

 
Reagents
Dulbecco’s modified Eagle’s medium (DMEM) and FBS were purchased from GIBCO-BRL. Ang II was purchased from the Peptide Institute. BSA was purchased from Sigma Chemical Co. [-³²P]dCTP was obtained from DuPont-NEN. CV11974, a specific AT₁-R antagonist, was obtained from Takeda Chemical Industries, Ltd. PD123319, a specific AT₂-R antagonist, was obtained from Warner-Lambert, Park Davis Co. Adenovirus vector expressing the dominant negative mutant of Rho-kinase (AdDNRhoK) has been described previously.¹⁶ Botulinum C3 exotoxin, a specific inhibitor of Rho, was purchased from Calbiochem.Y-27632, a specific inhibitor of Rho-kinase, was obtained from Yoshitomi Chemical Industries, Ltd. Antibodies against the phosphorylated form of extracellular signal-regulated protein kinase (ERK) and ERK were obtained from New England Biolabs. Unless indicated otherwise, other chemical reagents were purchased from Wako Pure Chemicals.

Cell Culture
VSMCs were isolated from the thoracic aortas of Sprague-Dawley rats and maintained as described previously.⁴ Passages 5 through 12 were used for the experiments. Cells were grown to confluence in DMEM with 10% FBS, growth-arrested in DMEM with 0.1% BSA for 2 days, and then used for the experiments.

Infection of AdDNRhoK
Confluent VSMCs were washed with PBS twice and incubated with AdDNRhoK at a multiplicity of infection (MOI) of 1 to 30 in PBS for 2 hours at room temperature. Cells were washed 3 times with PBS and incubated in DMEM with 0.1% BSA for 48 hours. Then the cells were stimulated with Ang II.

Northern Blot Analysis
Total RNA was prepared by an acid guanidinium-phenol-chloroform extraction method.¹⁷ Northern blot analyses of MCP-1 mRNA and 18S rRNA were performed as described previously.⁴ The radioactivity of the hybridized band of MCP-1 mRNA or rRNA was quantified with a Mac BAS bioimaging analyzer (FUJIFILM).

Quantification of Rat MCP-1 Protein by ELISA
The medium of nonstimulated or Ang II-stimulated VSMCs was collected and centrifuged at 12 000 rpm for 1 minute. The supernatant was stored at -70°C until assay. A sandwich ELISA for MCP-1 was carried out according to the method reported previously.¹⁸ Briefly, a microtiter plate was coated with mouse anti-rat MCP-1 monoclonal antibody B4 or C4 overnight at 4°C. The plate was washed with 0.05% Tween-20 in Tris-buffered saline (TBS, pH 7.5) and blocked with 0.2% of BSA in PBS. Then, serial dilutions of recombinant rat MCP-1 and test samples were applied to the plate. The incubation was performed at 37°C for 90 minutes, followed by a wash with 0.05% Tween 20 in TBS twice. Then rabbit polyclonal anti-rat MCP-1 antibody was added. After 90 minutes of incubation, the plate was washed twice with TBS. The alkaline phosphatase-labeled anti-rabbit IgG(ab')2 (Vector Laboratories) and p-nitrophenyl phosphate (Sigma) were added to the plate and incubated at 37°C for 30 minutes. The color was read spectrophotometrically at 405 nm.

Western Blot Analysis
VSMCs were lysed in a sample buffer (50 mmol/L NaCl, 30 mmol/L sodium phosphate, 50 mmol/L NaF, 5 mmol/L EDTA, 10 mmol/L Tris-HCl, pH 7.6, 1% Triton X, 0.5% pepstatin A, 0.2 U/mL aprotinin, 5 mmol/L leupeptin, and 1 mmol/L phenylmethylsulfonyl fluoride) after stimulation. Protein concentration was quantified by a BCA protein assay reagent (Pierce). Twenty micrograms of total protein was electrophoresed on 12% SDS-PAGE and transferred to polyvinylidene difluoride membrane (Immobilon, Millipore Co) electrophoretically (100 V, for 1 hour). Detection of phosphorylated ERK was performed by using enhanced chemiluminescence according to the manufacturer’s instructions (Amersham Pharmacia Biotech). It has been shown that phosphorylation of ERK is associated with the activation.¹⁹ Therefore, phosphorylation was taken as a measure of enzymatic activity. The membranes were stripped by incubation in a buffer containing 2% SDS, 100 mmol/L Tris-HCl, pH 7.4, and 100 mmol/L 2-mercaptoethanol at 70°C for 1 hour and reprobed with an antibody against ERK.

Statistical Analysis
Statistical analyses were performed by 1-way ANOVA and a multiple comparison (Fisher exact) test if appropriate. A value of P<0.05 was considered to be significant.

	Results

Top Abstract Introduction Methods Results Discussion References

 
Ang II Increased MCP-1 Production
VSMCs were stimulated with Ang II, and MCP-1 protein in the supernatant was measured by sandwich ELISA. As shown in Figure 1A, Ang II dose-dependently increased MCP-1 production at 12 hours of stimulation. CV11974 (10^-5 mol/L) inhibited the enhancement of MCP-1 protein expression by Ang II (10^-7 mol/L). However, PD 123,319 (10^-5 mol/L) did not show a significant effect (Figure 1B).

View larger version (27K): [in this window] [in a new window]   Figure 1. MCP-1 in the supernatant of cultured rat VSMCs. VSMCs were grown to confluence in 24-well plates and growth-arrested in DMEM with 0.1% BSA for 2 days. Then VSMCs were stimulated with Ang II for 12 hours, and production of MCP-1 in the supernatant was measured by sandwich ELISA. A, VSMCs were cultured with various concentrations of Ang II. B, VSMCs were cultured with Ang II after pretreatment with either an AT1-R antagonist (CV11974, 10-5 mol/L) or an AT2-R antagonist (PD123319, 10-5 mol/L) for 30 minutes. C, VSMCs were infected with AdDNRhoK or AdLacZ or preincubated with Y-27632 (30 minutes), C3 exotoxin (48 hours), or PD98059 (30 minutes). Then, cells were stimulated with Ang II for 12 hours. *P<0.05 vs control.

Expression of MCP-1 mRNA by Ang II
Next, we examined the effect of Ang II on MCP-1 mRNA expression. Figure 2A shows the time course of Ang II (10^-7 mol/L)-induced MCP-1 mRNA expression. The expression of MCP-1 mRNA reached peak at 3 to 6 hours after stimulation and then decreased. VSMCs were incubated with the various concentrations of Ang II indicated in Figure 2 for 6 hours. The expression of MCP-1 mRNA by Ang II stimulation was increased dose-dependently (Figure 2B). Preincubation with CV11974 (10^-5 mol/L) blocked the Ang II-induced MCP-1 mRNA expression. However, PD 123,319 (10^-5 mol/L) did not affect the expression (Figure 2C). These results indicate that Ang II stimulates MCP-1 expression through AT₁-R in VSMCs and are consistent with the expression of MCP-1 protein in the supernatants.

View larger version (38K): [in this window] [in a new window]   Figure 2. Expression of MCP-1 mRNA by Ang II. A, VSMCs were stimulated with Ang II (10-7 mol/L) for the indicated periods. Left, Ten micrograms of total RNA per lane was subjected to Northern blot analysis of MCP-1 mRNA and 18S rRNA. Right, Radioactivities of the bands were measured by an imaging analyzer. The radioactivity of MCP-1 mRNA was standardized by that of 18S rRNA mRNA. The control was designated as 1. Results are expressed as mean±SE (n=4). *P<0.05 vs control. B, VSMCs were cultured with various concentrations of Ang II (10-10 to 10-6 mol/L) or without Ang II for 6 hours. Left, Northern blot analysis was performed as in panel A. Right, Radioactivities of the bands were measured by an imaging analyzer. Results are expressed as mean±SE (n=4). *P<0.05 vs control. C, VSMCs were pretreated with either an AT1-R antagonist (CV11974, 10-5 mol/L) or an AT2-R antagonist (PD 123,319, 10-5 mol/L) for 30 minutes and then stimulated with Ang II (10-7 mol/L) for 6 hours. Left, Northern blot analysis was performed as in panel A. Right, Radioactivities of the bands were measured by an imaging analyzer. Results are expressed as mean±SE (n=4). *P<0.05 vs control.

Critical Role of Rho and Rho-Kinase in Ang II-Induced MCP-1 Expression
Recently, Ang II-induced Rho A activation was reported.²⁰ Therefore, we examined whether inhibition of the Rho pathway affected Ang II-induced MCP-1 expression. Botulinum C3 exotoxin, a specific inhibitor of Rho, inhibited Ang II-induced MCP-1 production (Figure 1C).

Next, we investigated whether Rho-kinase, a target molecule of Rho A, is involved in Ang II-induced MCP-1 expression. VSMCs were infected with AdDNRhoK at 30 MOI or preincubated with Y-27632 (10^-5 mol/L), a specific inhibitor of Rho-kinase, and then stimulated with Ang II (10^-7 mol/L) for 12 hours. As shown in Figure 1C, both AdDNRhoK and Y-27632 inhibited the Ang II-induced MCP-1 protein expression; however, the adenovirus vector expressing LacZ (AdLacZ, 30 MOI) that was used as a negative control did not show a significant effect. AdDNRhoK MOI-dependently suppressed the Ang II-induced MCP-1 mRNA expression (Figure 3). Y-27632 also suppressed the Ang II-induced MCP-1 mRNA expression as well.

View larger version (29K): [in this window] [in a new window]   Figure 3. Effect of Rho-kinase inhibition on Ang II-induced MCP-1 mRNA expression. VSMCs were cultured with or without Ang II (10-7 mol/L) for 6 hours after infection with AdDNRhoK (1 to 30 MOI) or AdLacZ (30 MOI) or preincubation with Y-27632 (10-5 mol/L, 30 minutes). A, Northern blot analysis was performed as in Figure 2A. B, Radioactivities of the bands were measured by an imaging analyzer. Results are expressed as mean±SE (n=4). *P<0.01 vs control; #P<0.01 vs AdLacZ+Ang II.

Y-27632 Did Not Affect Ang II-Induced ERK Activation
Previously, it has been reported that ERK is important for Ang II-induced MCP-1 expression.²¹ PD 098,059, a specific inhibitor of ERK kinase, inhibited Ang II-induced MCP-1 expression (Figure 1C), confirming the previous report. Therefore, we examined whether the Rho-kinase pathway affects Ang II-induced ERK activation. The Ang II-induced ERK activation was not inhibited by Y-27632 (Figure 4).

View larger version (26K): [in this window] [in a new window]   Figure 4. Effect of Rho-kinase inhibitor on Ang II-induced ERK activation. VSMCs were cultured with Ang II (10-7 mol/L) for 5 minutes after pretreatment with or without Y-27632 (10-5 mol/L). Phosphorylation of ERK was detected by Western blot analysis using a phospho-specific ERK antibody (top). The membrane was stripped and reprobed with an ERK antibody (bottom). The same results were obtained in other independent experiments (n=3), and a representative autoradiograph is shown.

	Discussion

Top Abstract Introduction Methods Results Discussion References

 
The major findings of the present study are that Ang II induces MCP-1 expression through AT₁-R in VSMCs and that the Rho-Rho-kinase pathway is critical for Ang II-induced MCP-1 expression.

Recently, it has been reported that Rho A plays an important role in Ang II-induced premyofibril formation by Ang II.¹⁵ However, the pathway linking AT₁-R and Rho A is not clear. Generally, there are few data involving the mechanism of activation of the Rho A guanine nucleotide exchange factor that activates Rho GTPase by extracellular ligand.²² Lysophosphatidic acid was reported to activate Rho through G13,²³ whereas thrombin activated Rho through G12.²⁴ It has been suggested that G directly binds to the Rho A guanine nucleotide exchange factor. Recently, it has been reported that AT₁-R is coupled with G13 in rat portal vein myocytes.²⁵ Although it is not clear whether the same G protein is coupled with AT₁-R in VSMCs, this pathway may link AT₁-R to Rho A. Another possibility is the epidermal growth factor (EGF) receptor-dependent pathway, because lysophosphatidic acid-induced Rho activation was blocked by a dominant negative version of the EGF receptor.²³ Transactivation of the EGF receptor by Ang II through AT₁-R is also reported to play a critical role in the signaling of AT₁-R.²⁶ Therefore, it may be possible that the EGF receptor-dependent pathway mediates Ang II-induced Rho A activation. However, further investigation is necessary to clarify the mechanisms for Ang II-induced Rho A and Rho-kinase activation.

Recently, a role of ERK in the induction of Ang II-induced MCP-1 expression has been reported.²¹ We confirmed the results of the previous report. Stretch-induced ERK activation was blocked by C3 exotoxin or Y-27632,²⁷ suggesting that the Rho-Rho-kinase pathway regulates stretch-induced ERK activation. However, we showed that Y-27632 did not affect the Ang II-induced ERK activation, and the result is consistent with that of the previous report.²⁰ These data suggest that Ang II differentially activates the Rho-kinase and ERK pathways. Although the possibility that the ERK pathway activates the Rho-Rho-kinase pathway is not excluded at this point, such an interaction has not been reported.

Rho has been shown to activate serum response factor-dependent transcription²⁸ and to activate nuclear factor (NF)-B, a transcription factor.²⁹ It has been shown that Ang II-induced MCP-1 expression is mediated by NF-B³⁰ because Ang II-induced MCP-1 expression was inhibited by pyrrolidone dithiocarbamate (PDTC), which is an antioxidant and an inhibitor of NF-B as well. However, Chen et al²¹ failed to observe the effect of PDTC on Ang II-induced MCP-1 expression. We also failed to observe the effect of PDTC on Ang II-induced MCP-1 expression in our VSMCs (data not shown), suggesting that NF-B may not play a dominant role in the induction of MCP-1 by Ang II. The role of serum response factor in MCP-1 gene transcription has not yet been reported. Therefore, further investigation is necessary to determine the Ang II-activated and Rho-kinase-dependent transcription factor that enhances MCP-1 gene transcription.

An increasing body of evidence suggests that monocytes and macrophages play an important role in the progression of atherosclerosis and in plaque instability as well. Disruption of the MCP-1 receptor caused attenuation of atherosclerosis when these mice were crossed with apoE knockout mice.¹¹ These results suggest the critical role of MCP-1 in atherogenesis. We demonstrated in the present study that Ang II-induced MCP-1 expression in VSMCs via ERK and Rho-kinase pathways. Therefore, it is possible that the beneficial effects of the ACE inhibitor, at least in part, are derived from the inhibition of Ang II-induced cytokine production, as shown in the present study and our previous report.⁴ Recently, Uehata et al¹⁴ reported that Y-27632 decreased blood pressure in hypertensive rats and proposed that Rho-kinase may be a target molecule for the treatment of hypertension. Our data suggest that inhibition of the Rho-kinase pathway by Y-27632 or AdDNRhoK may suppress the progression of atherosclerosis by inhibition of MCP-1 expression. Therefore, Rho-kinase may be a novel target for the treatment of high blood pressure and atherosclerosis as well.

	Acknowledgments

 
This study was supported in part by grants from Kaibara Morikazu Medical Science Promotion Foundation, Fukuoka, Japan; Uehara Memorial Foundation, Tokyo, Japan; and Welfide Medical Research Foundation, Osaka, Japan.

Received December 15, 2000; first decision December 28, 2000; accepted January 9, 2001.

	References

Top Abstract Introduction Methods Results Discussion References

 

1. Timmermans PBMWM, Wong PC, Chiu AT, Herblin WF, Benfield P, Carini DJ, Lee RJ, Wexler RR, Saye JAM, Smith RD. Angiotensin II receptors and angiotensin II receptor antagonists. Pharmacol Rev. 1993; 45: 205–251.[Medline] [Order article via Infotrieve]
2. Sasaki K, Yamano Y, Bardhan S, Iwai N, Murray JJ, Hasegawa M, Matsuda Y, Inagami T. Cloning and expression of a complementary DNA encoding a bovine adrenal angiotensin type 1 receptor. Nature. 1991; 351: 230–233.[Medline] [Order article via Infotrieve]
3. Kambayashi Y, Bardhan S, Takahashi K, Tsuzuki S, Inui H, Hamakubo T, Inagami T. Molecular cloning of a novel angiotensin II receptor isoform involved in phosphotyrosine phosphatase inhibition. J Biol Chem. 1993; 268: 24543–24546.[Abstract/Free Full Text]
4. Funakoshi Y, Ichiki T, Ito K, Takeshita A. Induction of interleukin-6 expression by angiotensin II in rat vascular smooth muscle cells. Hypertension. 1999; 34: 118–125.[Abstract/Free Full Text]
5. Yoshimura T, Robinson EA, Tanaka S, Appella E, Kuratsu J, Leonard EJ. Purification and amino acid analysis of two human glioma-derived monocyte chemoattractants. J Exp Med. 1989; 169: 1449–1459.[Abstract/Free Full Text]
6. Koch AE, Kunkel SL, Harlow LA, Mazarakis DD, Haines GK, Burdick MD, Pope RM, Walz A, Strieter RM. Epithelial neutrophil activating peptide-78: a novel chemotactic cytokine for neutrophils in arthritis. J Clin Invest. 1994; 94: 1012–1018.
7. Schall TJ, Bacon K, Toy KJ, Goeddel DV. Selective attraction of monocytes and T lymphocytes of the memory phenotype by cytokine RANTES. Nature. 1990; 347: 669–671.[Medline] [Order article via Infotrieve]
8. Nelken NA, Coughlin SR, Gordon D, Wilcox JN. Monocyte chemoattractant protein-1 in human atheromatous plaques. J Clin Invest. 1991; 88: 1121–1127.
9. Wenzel UO, Fouqueray B, Grandaliano G, Kim YS, Karamitsos C, Valente AJ, Abboud HE. Thrombin regulates expression of monocyte chemoattractant protein-1 in vascular smooth muscle cells. Circ Res. 1995; 77: 503–509.[Abstract/Free Full Text]
10. Wang JM, Sica A, Peri G, Walter S, Padura IM, Libby P, Ceska M, Lindley I, Colotta F, Mantovani A. Expression of monocyte chemotactic protein and interleukin-8 by cytokine-activated human vascular smooth muscle cells. Arterioscler Thromb. 1991; 11: 1166–1174.[Abstract/Free Full Text]
11. Boring L, Gosling J, Cleary M, Charo IF. Decreased lesion formation in CCR2-/- mice reveals a role for chemokines in the initiation of atherosclerosis. Nature. 1998; 394: 894–897.[Medline] [Order article via Infotrieve]
12. Shimokawa H. Cellular and molecular mechanisms of coronary artery spasm: lessons from animal models. Jpn Circ J. 2000; 64: 1–12.[Medline] [Order article via Infotrieve]
13. Feng J, Ito M, Ichikawa K, Isaka N, Nishikawa M, Hartshorne DJ, Nakano T. Inhibitory phosphorylation site for Rho-associated kinase on smooth muscle myosin phosphatase. J Biol Chem. 1999; 274: 37385–37390.[Abstract/Free Full Text]
14. Uehata M, Ishizaki T, Satoh H, Ono T, Kawahara T, Morishita T, Tamakawa H, Yamagami K, Inui J, Maekawa M, et al. Calcium sensitization of smooth muscle mediated by a Rho-associated protein kinase in hypertension. Nature. 1997; 389: 990–994.[Medline] [Order article via Infotrieve]
15. Aoki H, Izumo S, Sadoshima J. Angiotensin II activates RhoA in cardiac myocytes: a critical role of RhoA in angiotensin II-induced premyofibril formation. Circ Res. 1998; 82: 666–676.[Abstract/Free Full Text]
16. Hoshijima M, Sah VP, Wang Y, Chien KR, Brown JH. The low molecular weight GTPase Rho regulates myofibril formation and organization in neonatal rat ventricular myocytes. Involvement of Rho-kinase. J Biol Chem. 1998; 273: 7725–7730.[Abstract/Free Full Text]
17. Chomczynski P, Sacchi N. Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal Biochem. 1987; 162: 156–159.[Medline] [Order article via Infotrieve]
18. Yamashiro S, Takeya M, Nishi T, Kuratsu J, Yoshimura T, Ushio Y, Takahashi K. Tumor-derived monocyte chemoattractant protein-1 induces intratumoral infiltration of monocyte-derived macrophage subpopulation in transplanted rat tumors. Am J Pathol. 1994; 145: 856–867.[Abstract]
19. Aikawa R, Komuro I, Yamazaki T, Zou Y, Kudoh S, Tanaka M, Shiojima I, Hiroi Y, Yazaki Y. Oxidative stress activates extracellular signal-regulated kinases through Src and Ras in cultured cardiac myocytes of neonatal rats. J Clin Invest. 1997; 100: 1813–1821.[Medline] [Order article via Infotrieve]
20. Yamakawa T, Tanaka S, Numaguchi K, Yamakawa Y, Motley ED, Ichihara S, Inagami T. Involvement of Rho-kinase in angiotensin II-induced hypertrophy of rat vascular smooth muscle cells. Hypertension. 2000; 35: 313–318.[Abstract/Free Full Text]
21. Chen XL, Tummala PE, Olbrych MT, Alexander RW, Medford RM. Angiotensin II induces monocyte chemoattractant protein-1 gene expression in rat vascular smooth muscle cells. Circ Res. 1998; 83: 952–959.[Abstract/Free Full Text]
22. Kjoller L, Hall A. Signaling to Rho GTPases. Exp Cell Res. 1999; 253: 166–179.[Medline] [Order article via Infotrieve]
23. Gohla A, Harhammer R, Schultz G. The G-protein G13 but not G12 mediates signaling from lysophosphatidic acid receptor via epidermal growth factor receptor to Rho. J Biol Chem. 1998; 273: 4653–4659.[Abstract/Free Full Text]
24. Gohla A, Offermanns S, Wilkie TM, Schultz G. Differential involvement of Galpha12 and Galpha13 in receptor-mediated stress fiber formation. J Biol Chem. 1999; 274: 17901–17907.[Abstract/Free Full Text]
25. Macrez N, Morel JL, Kalkbrenner F, Viard P, Schultz G, Mironneau J. A betagamma dimer derived from G13 transduces the angiotensin AT1 receptor signal to stimulation of Ca²⁺ channels in rat portal vein myocytes. J Biol Chem. 1997; 272: 23180–23185.[Abstract/Free Full Text]
26. Eguchi S, Numaguchi K, Iwasaki H, Matsumoto T, Yamakawa T, Utsunomiya H, Motley ED, Kawakatsu H, Owada KM, Hirata Y, et al. Calcium-dependent epidermal growth factor receptor transactivation mediates the angiotensin II-induced mitogen-activated protein kinase activation in vascular smooth muscle cells. J Biol Chem. 1998; 273: 8890–8896.[Abstract/Free Full Text]
27. Numaguchi K, Eguchi S, Yamakawa T, Motley ED, Inagami T. Mechanotransduction of rat aortic vascular smooth muscle cells requires RhoA and intact actin filaments. Circ Res. 1999; 85: 5–11.[Abstract/Free Full Text]
28. Hill CS, Wynne J, Treisman R. The Rho family GTPases RhoA, Rac1, and CDC42Hs regulate transcriptional activation by SRF. Cell. 1995; 81: 1159–1170.[Medline] [Order article via Infotrieve]
29. Perona R, Montaner S, Saniger L, Sanchez-Perez I, Bravo R, Lacal JC. Activation of the nuclear factor-kappaB by Rho, CDC42, and Rac-1 proteins. Genes Dev. 1997; 11: 463–475[Abstract/Free Full Text]
30. Hernandez-Presa M, Bustos C, Ortego M, Tunon J, Renedo G, Ruiz-Ortega M, Egido J. Angiotensin-converting enzyme inhibition prevents arterial nuclear factor-kappa B activation, monocyte chemoattractant protein-1 expression, and macrophage infiltration in a rabbit model of early accelerated atherosclerosis. Circulation. 1997; 95: 1532–1541.[Abstract/Free Full Text]

This article has been cited by other articles:

				F. Yao, C. Sumners, S. T. O'Rourke, and C. Sun Angiotensin II increases GABAB receptor expression in nucleus tractus solitarii of rats Am J Physiol Heart Circ Physiol, June 1, 2008; 294(6): H2712 - H2720. [Abstract] [Full Text] [PDF]

				M. Takahashi, E. Suzuki, R. Takeda, S. Oba, H. Nishimatsu, K. Kimura, T. Nagano, R. Nagai, and Y. Hirata Angiotensin II and tumor necrosis factor-{alpha} synergistically promote monocyte chemoattractant protein-1 expression: roles of NF-{kappa}B, p38, and reactive oxygen species Am J Physiol Heart Circ Physiol, June 1, 2008; 294(6): H2879 - H2888. [Abstract] [Full Text] [PDF]

				J. F. Giani, M. M. Gironacci, M. C. Munoz, D. Turyn, and F. P. Dominici Angiotensin-(1-7) has a dual role on growth-promoting signalling pathways in rat heart in vivo by stimulating STAT3 and STAT5a/b phosphorylation and inhibiting angiotensin II-stimulated ERK1/2 and Rho kinase activity Exp Physiol, May 1, 2008; 93(5): 570 - 578. [Abstract] [Full Text] [PDF]

				P. Rivera, M. P. Ocaranza, S. Lavandero, and J. E. Jalil Rho Kinase Activation and Gene Expression Related to Vascular Remodeling in Normotensive Rats With High Angiotensin I Converting Enzyme Levels Hypertension, October 1, 2007; 50(4): 792 - 798. [Abstract] [Full Text] [PDF]

				S. Choudhary, M. Lu, R. Cui, and A. R. Brasier Involvement of a Novel Rac/RhoA Guanosine Triphosphatase-Nuclear Factor-{kappa}B Inducing Kinase Signaling Pathway Mediating Angiotensin II-Induced RelA Transactivation Mol. Endocrinol., September 1, 2007; 21(9): 2203 - 2217. [Abstract] [Full Text] [PDF]

				M. Ruperez, R. Rodrigues-Diez, L. M. Blanco-Colio, E. Sanchez-Lopez, J. Rodriguez-Vita, V. Esteban, G. Carvajal, J. J. Plaza, J. Egido, and M. Ruiz-Ortega HMG-CoA Reductase Inhibitors Decrease Angiotensin II-Induced Vascular Fibrosis: Role of RhoA/ROCK and MAPK Pathways Hypertension, August 1, 2007; 50(2): 377 - 383. [Abstract] [Full Text] [PDF]

				J.-P. Segain, M. Rolli-Derkinderen, N. Gervois, D. Raingeard de la Bletiere, G. Loirand, and P. Pacaud Urotensin II is a New Chemotactic Factor for UT Receptor-Expressing Monocytes J. Immunol., July 15, 2007; 179(2): 901 - 909. [Abstract] [Full Text] [PDF]

				M. Wang, J. Zhang, L.-Q. Jiang, G. Spinetti, G. Pintus, R. Monticone, F. D. Kolodgie, R. Virmani, and E. G. Lakatta Proinflammatory Profile Within the Grossly Normal Aged Human Aortic Wall Hypertension, July 1, 2007; 50(1): 219 - 227. [Abstract] [Full Text] [PDF]

				G. Chipitsyna, Q. Gong, C. F. Gray, Y. Haroon, E. Kamer, and H. A. Arafat Induction of Monocyte Chemoattractant Protein-1 Expression by Angiotensin II in the Pancreatic Islets and {beta}-Cells Endocrinology, May 1, 2007; 148(5): 2198 - 2208. [Abstract] [Full Text] [PDF]

				C. Doe, R. Bentley, D. J. Behm, R. Lafferty, R. Stavenger, D. Jung, M. Bamford, T. Panchal, E. Grygielko, L. L. Wright, et al. Novel Rho Kinase Inhibitors with Anti-inflammatory and Vasodilatory Activities J. Pharmacol. Exp. Ther., January 1, 2007; 320(1): 89 - 98. [Abstract] [Full Text] [PDF]

				H. Ohtsu, H. Suzuki, H. Nakashima, S. Dhobale, G. D. Frank, E. D. Motley, and S. Eguchi Angiotensin II Signal Transduction Through Small GTP-Binding Proteins: Mechanism and Significance in Vascular Smooth Muscle Cells Hypertension, October 1, 2006; 48(4): 534 - 540. [Full Text] [PDF]

				K. Ito, Y. Hirooka, Y. Kimura, Y. Sagara, and K. Sunagawa Ovariectomy Augments Hypertension Through Rho-Kinase Activation in the Brain Stem in Female Spontaneously Hypertensive Rats Hypertension, October 1, 2006; 48(4): 651 - 657. [Abstract] [Full Text] [PDF]

				R. Cui, B. Tieu, A. Recinos, R. G. Tilton, and A. R. Brasier RhoA Mediates Angiotensin II-Induced Phospho-Ser536 Nuclear Factor {kappa}B/RelA Subunit Exchange on the Interleukin-6 Promoter in VSMCs Circ. Res., September 29, 2006; 99(7): 723 - 730. [Abstract] [Full Text] [PDF]

				A. Douillette, A. Bibeau-Poirier, S.-P. Gravel, J.-F. Clement, V. Chenard, P. Moreau, and M. J. Servant The Proinflammatory Actions of Angiotensin II Are Dependent on p65 Phosphorylation by the I{kappa}B Kinase Complex J. Biol. Chem., May 12, 2006; 281(19): 13275 - 13284. [Abstract] [Full Text] [PDF]

				J. Winaver, E. Ovcharenko, I. Rubinstein, K. Gurbanov, P. Pollesello, B. Bishara, A. Hoffman, and Z. Abassi Involvement of Rho kinase pathway in the mechanism of renal vasoconstriction and cardiac hypertrophy in rats with experimental heart failure Am J Physiol Heart Circ Physiol, May 1, 2006; 290(5): H2007 - H2014. [Abstract] [Full Text] [PDF]

				A. Tedgui and Z. Mallat Cytokines in Atherosclerosis: Pathogenic and Regulatory Pathways Physiol Rev, April 1, 2006; 86(2): 515 - 581. [Abstract] [Full Text] [PDF]

				G. Loirand, P. Guerin, and P. Pacaud Rho Kinases in Cardiovascular Physiology and Pathophysiology Circ. Res., February 17, 2006; 98(3): 322 - 334. [Abstract] [Full Text] [PDF]

				K. K. Koh, S. H. Han, and M. J. Quon Inflammatory Markers and the Metabolic Syndrome: Insights From Therapeutic Interventions J. Am. Coll. Cardiol., December 6, 2005; 46(11): 1978 - 1985. [Abstract] [Full Text] [PDF]

				H. Shimokawa and A. Takeshita Rho-Kinase Is an Important Therapeutic Target in Cardiovascular Medicine Arterioscler. Thromb. Vasc. Biol., September 1, 2005; 25(9): 1767 - 1775. [Abstract] [Full Text] [PDF]

				K. Budzyn, P. D. Marley, and C. G. Sobey Opposing Roles of Endothelial and Smooth Muscle Phosphatidylinositol 3-Kinase in Vasoconstriction: Effects of Rho-Kinase and Hypertension J. Pharmacol. Exp. Ther., June 1, 2005; 313(3): 1248 - 1253. [Abstract] [Full Text] [PDF]

				T. Kishi, Y. Hirooka, A. Masumoto, K. Ito, Y. Kimura, K. Inokuchi, T. Tagawa, H. Shimokawa, A. Takeshita, and K. Sunagawa Rho-Kinase Inhibitor Improves Increased Vascular Resistance and Impaired Vasodilation of the Forearm in Patients With Heart Failure Circulation, May 31, 2005; 111(21): 2741 - 2747. [Abstract] [Full Text] [PDF]

				Y.-X. Wang, B. Martin-McNulty, V. da Cunha, J. Vincelette, X. Lu, Q. Feng, M. Halks-Miller, M. Mahmoudi, M. Schroeder, B. Subramanyam, et al. Fasudil, a Rho-Kinase Inhibitor, Attenuates Angiotensin II-Induced Abdominal Aortic Aneurysm in Apolipoprotein E-Deficient Mice by Inhibiting Apoptosis and Proteolysis Circulation, May 3, 2005; 111(17): 2219 - 2226. [Abstract] [Full Text] [PDF]

				P.-C. Lee, I-C. Ho, and T.-C. Lee Oxidative Stress Mediates Sodium Arsenite-Induced Expression of Heme Oxygenase-1, Monocyte Chemoattractant Protein-1, and Interleukin-6 in Vascular Smooth Muscle Cells Toxicol. Sci., May 1, 2005; 85(1): 541 - 550. [Abstract] [Full Text] [PDF]

				T. Kanda, K. Hayashi, S. Wakino, K. Homma, K. Yoshioka, K. Hasegawa, N. Sugano, S. Tatematsu, I. Takamatsu, T. Mitsuhashi, et al. Role of Rho-Kinase and p27 in Angiotensin II-Induced Vascular Injury Hypertension, April 1, 2005; 45(4): 724 - 729. [Abstract] [Full Text] [PDF]

				G. Loirand, M. Rolli-Derkinderen, and P. Pacaud RhoA and resistance artery remodeling Am J Physiol Heart Circ Physiol, March 1, 2005; 288(3): H1051 - H1056. [Abstract] [Full Text] [PDF]

				G. Spinetti, M. Wang, R. Monticone, J. Zhang, D. Zhao, and E. G. Lakatta Rat Aortic MCP-1 and Its Receptor CCR2 Increase With Age and Alter Vascular Smooth Muscle Cell Function Arterioscler. Thromb. Vasc. Biol., August 1, 2004; 24(8): 1397 - 1402. [Abstract] [Full Text] [PDF]

				E. Suzuki, H. Satonaka, H. Nishimatsu, S. Oba, R. Takeda, M. Omata, T. Fujita, R. Nagai, and Y. Hirata Myocyte Enhancer Factor 2 Mediates Vascular Inflammation via the p38-Dependent Pathway Circ. Res., July 9, 2004; 95(1): 42 - 49. [Abstract] [Full Text] [PDF]

				G. G. Neri Serneri, M. Boddi, P. A. Modesti, M. Coppo, I. Cecioni, T. Toscano, M. L. Papa, M. Bandinelli, G. F. Lisi, and M. Chiavarelli Cardiac Angiotensin II Participates in Coronary Microvessel Inflammation of Unstable Angina and Strengthens the Immunomediated Component Circ. Res., June 25, 2004; 94(12): 1630 - 1637. [Abstract] [Full Text] [PDF]